Protagonist Therapeutics Inc (PTGX)

08:51 AM

Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook - Benzinga

08:51 AM

02:56 AM

How Protagonist Therapeutics Inc. stock reacts to job market data2025 Winners & Losers & Verified Technical Signals - newser.com

02:56 AM

Oct 13, 2025

Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal - Zacks Investment Research

Oct 13, 2025

Oct 13, 2025

Johnson & Johnson Eyes Protagonist Therapeutics Acquisition, PTG - GuruFocus

Oct 13, 2025

Oct 13, 2025

Protagonist Therapeutics falls amid a report J&J deal price may be lower (PTGX:NASDAQ) - Seeking Alpha

Oct 13, 2025

Oct 13, 2025

J&J Could Be Latest Protagonist In M&A Merry-Go-Round - insights.citeline.com

Oct 13, 2025

Oct 13, 2025

Is Protagonist Therapeutics Inc. a candidate for recovery playTrade Risk Report & AI Driven Stock Reports - newser.com

Oct 13, 2025

Oct 13, 2025

How Protagonist Therapeutics Inc. stock responds to policy changes2025 Volatility Report & Consistent Growth Stock Picks - newser.com

Oct 13, 2025

Oct 13, 2025

Why Johnson & Johnson Is Eyeing Protagonist Therapeutics: The Rationale (NASDAQ:PTGX) - Seeking Alpha

Oct 13, 2025

Oct 13, 2025

Protagonist Therapeutics Reaches Analyst Target Price - Nasdaq

Oct 13, 2025

Oct 13, 2025

J&J in talks to acquire Protagonist Therapeutics - Yahoo Finance

Oct 13, 2025

Oct 13, 2025

Protagonist Therapeutics stock price target raised to $112 by BMO Capital - Investing.com Canada

Oct 13, 2025

Oct 13, 2025

News impact scoring models applied to Protagonist Therapeutics Inc.2025 Year in Review & Low Drawdown Momentum Ideas - newser.com

Oct 13, 2025

Oct 13, 2025

Protagonist Therapeutics, Inc. $PTGX Stock Position Cut by Inspire Investing LLC - MarketBeat

Oct 13, 2025

Oct 12, 2025

Using data models to predict Protagonist Therapeutics Inc. stock movementQuarterly Profit Review & Daily Price Action Insights - newser.com

Oct 12, 2025

Oct 12, 2025

Johnson & Johnson To Acquire Protagonist? It'd Be A Good Deal To Make - Seeking Alpha

Oct 12, 2025

Oct 12, 2025

Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 - Cincinnati Enquirer

Oct 12, 2025

Oct 11, 2025

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill - Pensacola News Journal

Oct 11, 2025

Oct 11, 2025

Protagonist Therapeutics (PTGX) Surges on Johnson & Johnson Acquisition Talks - GuruFocus

Oct 11, 2025

Oct 11, 2025

Key deals this week: Protagonist Therapeutics, Bristol Myers, Novo Nordisk, Fifth Third Bancorp and more - Seeking Alpha

Oct 11, 2025

Oct 11, 2025

Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today - sharewise.com

Oct 11, 2025

Oct 11, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Up 9.4%What's Next? - MarketBeat

Oct 11, 2025

Oct 11, 2025

Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials - ts2.tech

Oct 11, 2025

Oct 11, 2025

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) 51% Price Boost Is Out Of Tune With Revenues - simplywall.st

Oct 11, 2025

Oct 11, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Sets New 12-Month HighHere's What Happened - MarketBeat

Oct 11, 2025

Oct 10, 2025

Protagonist Therapeutics Inc. (PTGX) Stock Price | Live Quotes & Charts | NSD - StocksToTrade

Oct 10, 2025

Oct 10, 2025

Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025 - Newport Daily News

Oct 10, 2025

Oct 10, 2025

Pharma, Battery, And Biotech Stocks See Sudden Price Jumps - Finimize

Oct 10, 2025

Oct 10, 2025

Protagonist Therapeutics (PTGX) Surges on Takeover Speculation - GuruFocus

Oct 10, 2025

Oct 10, 2025

Johnson & Johnson in talks to acquire Protagonist Therapeutics, source says - WSAU

Oct 10, 2025

Oct 10, 2025

Protagonist Therapeutics Stock Notable Surge - timothysykes.com

Oct 10, 2025

Oct 10, 2025

Protagonist Therapeutics’s Recent Commendable Performance - StocksToTrade

Oct 10, 2025

Oct 10, 2025

Protagonist Therapeutics stock reaches all-time high at 73.34 USD By Investing.com - Investing.com Nigeria

Oct 10, 2025

Oct 10, 2025

Sudden Surge: PTGX’s Momentous Journey - timothysykes.com

Oct 10, 2025

Oct 10, 2025

Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs - ts2.tech

Oct 10, 2025

Oct 10, 2025

Protagonist Therapeutics stock reaches all-time high at 73.34 USD - Investing.com

Oct 10, 2025

Oct 10, 2025

Protagonist Therapeutics Sees Surging Stock Price: What’s Driving This? - StocksToTrade

Oct 10, 2025

Oct 10, 2025

Why Did Protagonist Therapeutics Stock Soar Today? - MSN

Oct 10, 2025

Oct 10, 2025

Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report - Benzinga

Oct 10, 2025

Oct 10, 2025

Protagonist Therapeutics (PTGX) Stock Surges Over 34% - GuruFocus

Oct 10, 2025

Oct 10, 2025

Johnson & Johnson in Acquisition Talks with Protagonist TherapeuticsNews and Statistics - IndexBox

Oct 10, 2025

Oct 10, 2025

Stocks making the biggest moves midday: MP Materials, Alibaba, Protagonist Therapeutics & more - CNBC

Oct 10, 2025

Oct 10, 2025

Johnson & Johnson in Talks to Buy Protagonist Therapeutics: WSJ - Bloomberg.com

Oct 10, 2025

Oct 10, 2025

Protagonist Therapeutics (PTGX) Surges on Potential Johnson & Johnson Acquisition - GuruFocus

Oct 10, 2025

Oct 10, 2025

Protagonist Therapeutics stock surges after J&J acquisition talks report - Yahoo Finance

Oct 10, 2025

Oct 10, 2025

Protagonist Therapeutics surges after media reports J&J in talks to buy co - TradingView

Oct 10, 2025

Oct 10, 2025

J&J reportedly in talks to buy Protagonist (JNJ:NYSE) - Seeking Alpha

Oct 10, 2025

Oct 10, 2025

Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports - Yahoo Finance

Oct 10, 2025

Oct 10, 2025

Protagonist Therapeutics stock surges after J&J acquisition talks report By Investing.com - Investing.com South Africa

Oct 10, 2025

Oct 10, 2025

Johnson & Johnson In Talks To Buy Protagonist TherapeuticsWSJ - TradingView

Oct 10, 2025